So far, most Phase II trials have been designed and analysed under a frequentist framework. Under this framework, a trial is designed so that the overall Type I and Type II errors of the trial are controlled at some desired levels. Recently, a number of articles have advocated the use of Bayesian designs in practice. Under a Bayesian framework, a trial is designed so that the trial stops when the posterior probability of treatment is within certain prespecified thresholds. In this article, we argue that trials under a Bayesian framework can also be designed to control frequentist error rates. We introduce a Bayesian version of Simon’s well-known two-stage design to achieve this goal. We also consider two other errors, which are called Bayes...
Clinical trials play vital roles in drug development. Traditionally, phase II and phase III studies ...
Clincal trial designs often incorporate a sequential stopping rule to serve as a guide in the early ...
Early phase clinical trial designs have long been the focus of interest for clinicians and statistic...
So far, most Phase II trials have been designed and analysed under a frequentist framework. Under th...
Trials run in either rare diseases or rare subpopulations of common diseases are challenging in term...
The rate of failure in phase III oncology trials is surprisingly high, partly due to inadequate phas...
Background There is a growing interest in the use of Bayesian adaptive designs in late-phase clinic...
Background: There is a growing interest in the use of Bayesian adaptive designs in late-phase clinic...
With the revolutionary achievement in molecular targeted therapies and cancer immunotherapies, the t...
There is growing interest in Bayesian clinical trial designs with informative prior distributions, e...
International audienceIn controlled clinical trials, where minimizing treatment failures is crucial,...
In the conduct of sequential clinical trials, primary statistical issues include design, monitoring ...
The Simon's two-stage design is the most commonly applied among multi-stage designs in phase IIA cli...
Experimental design represents the typical context in which the interplay between Bayesian and frequ...
Randomized Controlled Trials (RCTs) are considered the gold standard for evaluating medical interven...
Clinical trials play vital roles in drug development. Traditionally, phase II and phase III studies ...
Clincal trial designs often incorporate a sequential stopping rule to serve as a guide in the early ...
Early phase clinical trial designs have long been the focus of interest for clinicians and statistic...
So far, most Phase II trials have been designed and analysed under a frequentist framework. Under th...
Trials run in either rare diseases or rare subpopulations of common diseases are challenging in term...
The rate of failure in phase III oncology trials is surprisingly high, partly due to inadequate phas...
Background There is a growing interest in the use of Bayesian adaptive designs in late-phase clinic...
Background: There is a growing interest in the use of Bayesian adaptive designs in late-phase clinic...
With the revolutionary achievement in molecular targeted therapies and cancer immunotherapies, the t...
There is growing interest in Bayesian clinical trial designs with informative prior distributions, e...
International audienceIn controlled clinical trials, where minimizing treatment failures is crucial,...
In the conduct of sequential clinical trials, primary statistical issues include design, monitoring ...
The Simon's two-stage design is the most commonly applied among multi-stage designs in phase IIA cli...
Experimental design represents the typical context in which the interplay between Bayesian and frequ...
Randomized Controlled Trials (RCTs) are considered the gold standard for evaluating medical interven...
Clinical trials play vital roles in drug development. Traditionally, phase II and phase III studies ...
Clincal trial designs often incorporate a sequential stopping rule to serve as a guide in the early ...
Early phase clinical trial designs have long been the focus of interest for clinicians and statistic...